

**Dear Doctor**  
You are cordially invited to join us on  
17 May 2023 (Wed)

## CME Talk

7:00pm – 7:25pm | Dr Rafael ROSELL from Spain

Title Topic : Therapeutic Strategies for Oncogenic KRAS Non-Small Cell Lung Cancer

7:25pm – 7:45pm | Dr Zahra DANTES from Germany

Title Topic : Onco-PDO Test Utilizing Patient-Derived Organoids (PDOs) Support Next-Generation Precision Oncology in Cancer Patients

7:45pm – 8:10pm | Dr POON Ming Chun Darren from Hong Kong

Title Topic : Patient-Derived Organoids for Cancer Drug Matching – Clinical Case Sharing

Online – via Zoom

Please Scan QR code or [click](#) here to register. Thank you for your participation !



SCAN ME

# Dr Rafael ROSELL



Dr. Rafael Rosell is Head of the Molecular and Cellular Oncology Laboratory program at the Germans Trias i Pujol Research Institute and Hospital (IGTP), Campus Can Ruti, (Badalona, Barcelona, Spain), past Director of the Cancer Biology and Precision Medicine Program at the Catalan Institute of Oncology, Hospital Germans Trias i Pujol (Badalona), Chief Scientific Officer, Chairman and Founder of Pangaea Oncology SL (Barcelona), Chief Medical Officer and President of the Dr Rosell Oncology Institute (IOR), Quirón Dexeus, General de Catalunya & Sagrat Cor Univ. Hospitals (Barcelona), and Founder and President of the Molecular Oncology Research Foundation (Barcelona). He is Founder and Director of International Relations and Projects, Spanish Lung Cancer Group (SLCG), member of the Foundation Council and Steering Committee of the European Thoracic Oncology Platform (ETOP) and on the Foundation Board of the ETOP- International Breast Cancer Study Group (IBCSG). He is also a Panel member of the ASCO Clinical Practice Living Guidelines- Systemic Therapy for Stage IV NSCLC.

Dr. Rosell's contributions to translational medical oncology, with particular emphasis in the field of non-small-cell lung cancer with EGFR mutations, have earned him international renown.

# Dr Zahra DANTES



Chief Scientific Officer, Invitrocue globally

Dr. Zahra Dantes, based in Munich, Germany, is the Chief Scientific Officer (CSO) of Invitrocue globally. She is a highly regarded expert in PDO technology (plus 10 years of experience) and cancer research (plus 15 years of experience) and has played a pivotal role in establishing our Invitrocue lab in Munich. As the CSO, Dr. Dantes leads the multinational scientific team in her leadership and management role and oversees all scientific, clinical, and pharmacology projects. Dr. Dantes holds a Ph.D. from the Medical Faculty of the Technical University of Munich (TUM). She also holds doctoral degrees in Veterinary Medicine (DVM) and Veterinary Science in Pathology (DVSc). In 2014, Dr. Dantes visited Cold Spring Harbor Laboratory in New York to further discover PDO technology. She is an author and co-author of several publications in prestigious journals and a member of the European Society for Medical Oncology (ESMO) and the American Society for Clinical Oncology (ASCO).

# Dr POON Ming Chun Darren



**Honorary Clinical Associate Professor at the Chinese University of Hong Kong**  
**Honorary Consultant in Clinical Oncology at Hong Kong Sanatorium & Hospital**  
**Honorary Consultant in Clinical Oncology at Princes of Wales Hospital, Hong Kong**

Dr Poon has several specialist areas of expertise, which include genitourinary (GU) cancer, neuro-oncology, hepato-pancreatic cancer, and head and neck cancer. His research interests include novel therapies for GU cancers, image-guided radiotherapy and stereotactic body radiotherapy (SBRT) for prostate, central nervous system tumor, pancreatic and liver cancer. Dr Poon pioneered the use of SBRT in the treatment of prostate cancer in Hong Kong and completed the first-in-Asia randomized study for prostate SBRT. He has published more than 50 original papers, scientific reviews, and abstracts in peer-reviewed journals and has co-authored the 10<sup>th</sup> edition of Fast Facts : Prostate Cancer. He is one of the expert panel in the Advanced Prostate Cancer Consensus Conference (APCCC) from 2019 onwards, and the Asia Pacific Advanced Consensus Conference (APAC-APCCC) from 2020 onwards. Dr Poon has been an invited speaker at local and regional, and international conferences and is currently involved in several clinical trials investigating new therapies for urothelial, bladder, renal and prostate cancers.

In addition to his clinical and academic duties, Dr Poon has been Vice-President of several professional societies, including the Hong Kong Society of Uro-Oncology, Hong Kong Nasopharyngeal Carcinoma Study Group and the Hong Kong SBRT study group. In addition, he is a Council Member of the Hong Kong Prostate Foundation and Vice-Chairman of the Hand in Hand Cancer Foundation.



# thank you

Contact Person : Emily Cheung

Email : [emily.cheung@invitrocue.com](mailto:emily.cheung@invitrocue.com)

Whatsapp : 9489-8033

